- Home
- JRVR vs ARMP Comparison
JRVR vs ARMP Comparison
Compare JRVR & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | ARMP |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 199.7M |
| IPO Year | 2014 | 1996 |
Fundamental Metrics
Financial Performance| Metric | JRVR | ARMP |
|---|---|---|
| Price | $3.95 | $4.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.33 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 206.5K | 74.7K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $687,614,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.74 | $2.88 |
| 52 Week High | $7.20 | $14.98 |
Technical Indicators
Market Signals| Indicator | JRVR | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 54.05 |
| Support Level | $3.82 | $3.98 |
| Resistance Level | $4.26 | $5.63 |
| Average True Range (ATR) | 0.12 | 0.52 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 42.23 | 41.37 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.